1 Citations (Scopus)

Abstract

Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731–1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.

Original languageEnglish
JournalTrends in Immunology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Anti-Idiotypic Antibodies
NK Cell Lectin-Like Receptor Subfamily C
T-Lymphocytes
Neoplasms
Cell Proliferation
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{8eb92ef513004c44a9dad64205b353ad,
title = "Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board",
abstract = "Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731–1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.",
author = "Mingari, {Maria Cristina} and Gabriella Pietra and Lorenzo Moretta",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.it.2018.12.009",
language = "English",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Immune Checkpoint Inhibitors

T2 - Anti-NKG2A Antibodies on Board

AU - Mingari, Maria Cristina

AU - Pietra, Gabriella

AU - Moretta, Lorenzo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731–1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.

AB - Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731–1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.

UR - http://www.scopus.com/inward/record.url?scp=85059231900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059231900&partnerID=8YFLogxK

U2 - 10.1016/j.it.2018.12.009

DO - 10.1016/j.it.2018.12.009

M3 - Article

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

ER -